BioXcel Therapeutics, Inc. (BTAI) NASDAQ
1.23
+0.07(+6.03%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.23
+0.07(+6.03%)
Currency In USD
| Previous Close | 1.16 |
| Open | 1.16 |
| Day High | 1.27 |
| Day Low | 1.15 |
| 52-Week High | 8.08 |
| 52-Week Low | 1.01 |
| Volume | 784,489 |
| Average Volume | 1.64M |
| Market Cap | 37.98M |
| PE | -0.26 |
| EPS | -4.77 |
| Moving Average 50 Days | 1.18 |
| Moving Average 200 Days | 1.99 |
| Change | 0.07 |
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
GlobeNewswire Inc.
Mar 11, 2026 8:20 PM GMT
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced the clo
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
GlobeNewswire Inc.
Mar 10, 2026 6:36 PM GMT
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that i
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
GlobeNewswire Inc.
Mar 05, 2026 12:00 PM GMT
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal Opioid use disorder is a gl